Black Diamond Therapeutics Inc. is getting $70 million up front and could earn up to $710 million in milestone payments in a deal with Servier for phase I-stage BDTX-4933, a small-molecule candidate ...

In this GTP-bound, active, state, Ras binds with high affinity to a set of cytoplasmic target or ‘effector’ proteins that initiate distinct intracellular signalling cascades. The Raf kinases ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

Currently, in Phase 1 development, BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. In a market dominated by tariff tensions, geopolitical surprises, and Fed uncertainty ...

Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster ...